Tyche Wealth Partners LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Tyche Wealth Partners LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,086 shares of the company's stock, valued at approximately $1,799,000.

Several other institutional investors and hedge funds also recently made changes to their positions in LLY. JGP Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company's stock worth $1,074,000 after purchasing an additional 16 shares in the last quarter. Cassia Capital Partners LLC grew its stake in Eli Lilly and Company by 1.8% during the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company's stock valued at $511,000 after acquiring an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC grew its stake in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company's stock valued at $334,000 after acquiring an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC grew its stake in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company's stock valued at $335,000 after acquiring an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. grew its stake in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company's stock valued at $688,000 after acquiring an additional 17 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $4.21 during trading hours on Tuesday, reaching $746.56. The company had a trading volume of 2,569,130 shares, compared to its average volume of 3,085,273. The business has a fifty day moving average price of $762.68 and a 200-day moving average price of $655.54. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78. The firm has a market cap of $709.35 billion, a PE ratio of 128.34, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the business posted $2.09 earnings per share. The business's revenue for the quarter was up 28.1% on a year-over-year basis. Sell-side analysts predict that Eli Lilly and Company will post 12.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm's stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company's stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on LLY. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an "overweight" rating in a research note on Friday, February 16th. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research note on Wednesday, February 7th. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a "neutral" rating in a research note on Thursday, April 11th. Cantor Fitzgerald reissued an "overweight" rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. Finally, Truist Financial reissued a "buy" rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.